Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
SAVA Cassava Sciences, Inc. daily Stock Chart
SAVA [NASD]
Cassava Sciences, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-0.22 Insider Own16.02% Shs Outstand17.23M Perf Week5.03%
Market Cap32.39M Forward P/E13.93 EPS next Y0.14 Insider Trans0.00% Shs Float15.20M Perf Month50.41%
Income-3.80M PEG- EPS next Q-0.13 Inst Own41.20% Short Float11.18% Perf Quarter48.03%
Sales- P/S- EPS this Y66.30% Inst Trans8.98% Short Ratio2.12 Perf Half Y57.98%
Book/sh1.02 P/B1.84 EPS next Y141.90% ROA-19.70% Target Price4.50 Perf Year74.07%
Cash/sh1.03 P/C1.82 EPS next 5Y- ROE-20.70% 52W Range0.76 - 2.55 Perf YTD121.18%
Dividend- P/FCF- EPS past 5Y-16.30% ROI- 52W High-26.27% Beta1.89
Dividend %- Quick Ratio20.10 Sales past 5Y- Gross Margin- 52W Low147.37% ATR0.17
Employees9 Current Ratio20.10 Sales Q/Q- Oper. Margin- RSI (14)76.01 Volatility11.22% 10.24%
OptionableNo Debt/Eq0.00 EPS Q/Q61.70% Profit Margin- Rel Volume1.63 Prev Close1.88
ShortableYes LT Debt/Eq0.00 EarningsJan 28 BMO Payout- Avg Volume801.24K Price1.88
Recom2.00 SMA2024.18% SMA5038.24% SMA20050.54% Volume1,306,326 Change0.00%
Dec-10-19 07:42AM  Top Ranked Momentum Stocks to Buy for December 10th Zacks
Dec-06-19 03:08PM  Alzheimers expert says more clinical trials are needed for controversial Biogen drug MarketWatch
10:58AM  Cassava stock is up on Alzheimer's data MarketWatch
07:39AM  The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend Benzinga
Dec-05-19 09:00PM  Cassava Sciences Announces Additional Positive Phase 2a Clinical Data in Alzheimers Disease at CTAD 2019 GlobeNewswire
Dec-04-19 09:26AM  Top Ranked Momentum Stocks to Buy for December 4th Zacks
Dec-01-19 09:30AM  The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More Benzinga
Nov-05-19 12:06PM  We Think Cassava Sciences (NASDAQ:SAVA) Can Easily Afford To Drive Business Growth Simply Wall St.
Oct-29-19 08:15AM  Cassava Sciences Announces Recent Clinical Highlights and Third Quarter 2019 Financial Results GlobeNewswire +5.51%
Oct-24-19 08:30AM  Cassava Sciences Clinical Results in Alzheimers Selected as Late-Breaking News at CTAD 2019 GlobeNewswire +5.99%
Sep-20-19 10:02AM  6 Small Drug Stocks in Focus Ahead of World Alzheimer's Day Zacks -8.46%
Sep-16-19 08:30AM  Cassava Sciences Initiates Phase 2b Clinical Study in Alzheimers Patients GlobeNewswire
Sep-09-19 02:42PM  Failure of Alzheimers Disease Study Creates a New Penny Stock Bloomberg -12.86%
12:17PM  A Look At Benzinga Pro's Most-Searched Tickers For September 9, 2019 Benzinga
07:30AM  Cassava Sciences Reports Positive Phase 2a Clinical Results in Alzheimers Patients GlobeNewswire
Sep-06-19 11:50AM  How Cassava Sciences, Inc. (NASDAQ:SAVA) Can Impact Your Portfolio Volatility Simply Wall St. +10.24%
Sep-03-19 08:30AM  Cassava Sciences to Present at H.C. Wainwrights 21st Annual Global Investment Conference GlobeNewswire +17.86%
Aug-12-19 08:30AM  Cassava Sciences Announces Second Quarter 2019 Financial Results GlobeNewswire -6.77%
Jul-08-19 02:51PM  What Kind Of Shareholder Owns Most Cassava Sciences, Inc. (NASDAQ:SAVA) Stock? Simply Wall St.
Jun-18-19 08:30AM  Cassava Sciences to Present at Maxim Groups Conference on Alzheimers Disease GlobeNewswire
May-28-19 08:29AM  Cassava Sciences Announces New Website Launch GlobeNewswire
May-23-19 04:35PM  Weekly CFO Buys Highlight GuruFocus.com
May-16-19 10:36AM  Cassava Sciences, Inc. (NASDAQ:SAVA) Insiders Increased Their Holdings Simply Wall St.
Apr-29-19 08:30AM  Cassava Sciences Reports First Quarter 2019 Financial Results GlobeNewswire
Apr-15-19 08:30AM  Cassava Sciences Completes Patient Enrollment for a Phase 2a Study in Patients with Alzheimers Disease GlobeNewswire
Cassava Sciences, Inc., a clinical-stage drug development company, develops drugs for nervous system disorders. The company's lead therapeutic product candidate PTI-125, a small molecule drug that is in Phase II clinical trial for the treatment of Alzheimer's disease. It is also developing PTI-125Dx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.
open in yahoo | open in reuters | open in google